The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34749 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Elvina Almuradova und 22 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Medical Oncology, Ege University, Izmir, Turkey. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Metastatic castration‐resistant prostate cancer (mCRPC) remains a challenging condition to treat despite recent advancements. This retrospective study aimed to assess the activity and tolerability of Lutetium‐177 (Lu‐177) PSMA‐617 radioligand therapy (RLT) in mCRPC patients across multiple cancer centers in Turkey. The study included 165 patients who received at least one cycle of Lu‐177 PSMA‐617 RLT, with the majority having bone metastases and undergone prior treatments. Prostate‐specific antigen (PSA) levels were assessed before each treatment cycle, and the biochemical response was evaluated in accordance with the Prostate Cancer Work Group 3 Criteria. The PSA decline of ≥50% was classified as a response, while an increase of ≥25% in PSA levels was indicative of progressive disease. Neither response nor progression was considered as stable disease. The Lu‐177 PSMA‐617 RLT led to a significant PSA response, with 50.6% of patients achieving a >50% decrease in PSA levels. Median overall survival (OS) and progression‐free survival were 13.5 and 8.2 months, respectively. Patients receiving Lu‐177 PSMA‐617 RLT in combination with androgen receptor pathway inhibitors (ARPIs) had a higher OS compared to those receiving Lu‐177 PSMA‐617 RLT alone (18.2 vs 12.3 months, P = .265). The treatment was generally well‐tolerated, with manageable side effects such as anemia and thrombocytopenia. This study provides real‐world evidence supporting the effectiveness and safety of Lu‐177 PSMA‐617 RLT in mCRPC patients, particularly when used in combination with ARPIs. These findings contribute to the growing body of evidence on the potential benefits of PSMA‐targeted therapies in advanced prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Medical Oncology, Ege University, Izmir, Turkey.
- Faculty of Medicine, Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey.
- Department of Medical Oncology, Gaziantep University Sahinbey Research and Application Hospital, Gaziantep, Turkey.
- Department of Nuclear Medicine, Nigde Omer Halisdemir University Training and Research Hospital, Nigde, Turkey.
- Faculty of Medicine, Department of Medical Oncology, Medeniyet University, Istanbul, Turkey.
- Department of Medical Oncology, Canakkale Mehmet Akif Ersoy State Hospital, Canakkale, Turkey.
ORCID-Profile: Elvina Almuradova, Serdar Celik
Zitieren
APA
Almuradova, E., Seyyar, M., Arak, H., Tamer, F., Kefeli, U., Koca, S., Sen, E., Telli, T. A., Karatas, F., Gokmen, I., Turhal, N. S., Sakalar, T., Ayhan, M., Ekinci, F., Hafizoglu, E., Kahraman, S., Kesen, O., Unal, C., Alan, O., …, & Gokmen, E. (2024). The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study. International Journal of Cancer. https://doi.org/10.1002/ijc.34749
Vancouver
Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, et al. The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study. International Journal of Cancer. 2024. doi:10.1002/ijc.34749
BibTeX
@article{Almuradova2024,
author = {Almuradova, Elvina and Seyyar, Mustafa and Arak, Hacı and Tamer, Fatih and Kefeli, Umut and Koca, Sinan and Sen, Erdem and Telli, Tugba Akin and Karatas, Fatih and Gokmen, Ivo and Turhal, Nazım Serdar and Sakalar, Teoman and Ayhan, Murat and Ekinci, Ferhat and Hafizoglu, Emre and Kahraman, Seda and Kesen, Oguzhan and Unal, Caglar and Alan, Ozkan and Celik, Serdar and Yekeduz, Emre and Omur, Ozgür and Gokmen, Erhan},
title = {The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34749}
}
EUVIMED